Acarbose vs Metformin

Mechanism

Acarbose is a complex oligosaccharide that competitively inhibits alpha-glucosidase enzymes (maltase, isomaltase, sucrase, glucoamylase) in the brush border of the small intestinal enterocytes, delaying the digestion and absorption of dietary carbohydrates. This blunts postprandial glucose and insulin spikes, reducing glycemic variability. In the longevity context, chronic postprandial glucose/insulin reduction mimics aspects of caloric restriction signaling, potentially reducing mTOR activation, AGE formation, and oxidative stress. Undigested carbohydrates reaching the colon serve as prebiotics, increasing short-chain fatty acid (SCFA) production by gut bacteria.

Standard Dosing

Research indicates 25-100 mg taken with the first bite of each carbohydrate-containing meal, up to 3 times daily.

Timing

Must be taken with the first bite of a carbohydrate-containing meal — timing is critical for mechanism of action. Ineffective if taken without carbohydrates or after the meal.

Cycle Duration

Ongoing for longevity applications. Long-term use is well-established in diabetes management.

Side Effects

• Flatulence and bloating (very common — from colonic fermentation of undigested carbohydrates)
• Diarrhea
• Abdominal pain and cramping
• Elevated liver transaminases (rare, reversible — typically at doses >100 mg TID)

Contraindications

• Inflammatory bowel disease (Crohn's, ulcerative colitis)
• Intestinal obstruction or predisposition to obstruction
• Chronic intestinal diseases with maldigestion/malabsorption
• Severe renal impairment (creatinine >2.0 mg/dL)
• Cirrhosis
• Known hypersensitivity to acarbose
• GI intolerance
• IBD or bowel obstruction

Best Stacking Partners

Mechanism

Metformin activates AMP-activated protein kinase (AMPK) via inhibition of mitochondrial Complex I, increasing the AMP/ATP ratio. AMPK activation triggers a cascade of metabolic effects: inhibition of hepatic gluconeogenesis, enhanced glucose uptake in skeletal muscle via GLUT4 translocation, and suppression of mTORC1 signaling. In the longevity context, metformin's mTOR inhibition mimics caloric restriction signaling, activating autophagy, reducing inflammatory cytokines (IL-6, TNF-a), decreasing insulin and IGF-1 signaling, and modulating the gut microbiome (increasing Akkermansia muciniphila). It also reduces AGE formation and mitochondrial ROS production.

Standard Dosing

Research indicates 500-1000 mg daily for longevity/anti-aging protocols. Standard diabetes dosing: 500-2550 mg daily.

Timing

Take with food (dinner) to minimize GI side effects. Extended-release formulation once daily with dinner. Immediate-release split into 2-3 doses with meals.

Cycle Duration

Ongoing for longevity applications. The TAME (Targeting Aging with Metformin) trial is designed to assess long-term geroprotective effects.

Side Effects

• GI distress: nausea, diarrhea, bloating, metallic taste (common initially, improves with XR formulation)
• Vitamin B12 deficiency (with chronic use — monitor annually)
• Lactic acidosis (rare but serious — primarily in renal impairment)
• Potential blunting of exercise-induced mitochondrial adaptations (debated)
• Weight loss (often considered a benefit)

Contraindications

• eGFR <30 mL/min/1.73m2 (contraindicated) or <45 (use with caution)
• Acute or chronic metabolic acidosis including lactic acidosis
• Heavy alcohol consumption
• Acute decompensated heart failure
• Hepatic failure
• Planned procedures with iodinated contrast dye

Best Stacking Partners